Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quan Du Zhong Capsule for sudden sensorineural hearing loss with kidney essence deficiency
ChiCTR2300075204Phase 4Not yet recruiting
- Sponsor
- Taizhou People's Hospital
- Start
- Apr 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Quanduzhong in acute sensorineural hearing loss (4 arms), sponsored by Taizhou People's Hospital. Primary endpoint: Clinical Symptom Grading Quantitative Score. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
Quanduzhong
03
Conditions
acute sensorineural hearing loss
Beyond the preview
Go deeper on ChiCTR2300075204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075204.